OptiNose today announced the U.S. Food and Drug Administration has accepted for review the company’s New Drug Application (NDA) for the investigational new product OPN-375 for the treatment of nasal polyposis in adults.
Teva Pharmaceutical Industries Ltd. announced FDA approval of two products for adolescent and adult patients with asthma: AirDuo RespiClick and ArmonAir RespiClick.
Incyte Corporation and Calithera Biosciences Inc. announced that the companies have entered into a global collaboration and license agreement for the research, development and commercialization of Calithera’s first-in-class, small molecule arginase inhibitor CB-1158 in hematology and oncology.
Pfizer Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion recommending XELJANZ (tofacitinib citrate) 5 mg twice daily for the treatment of patients with moderate to severe active rheumatoid arthritis.
In a letter to Congress and the Administration, leading healthcare organizations called for a renewed effort to move to value-based, patient-centered payment models that reward improved quality and cost-effective care. Central to this effort is addressing the perverse incentives in the fee-for-service system, and antiquated laws and regulations that impede innovation and care coordination.
The U.S. FDA granted final approval to Aurobindo Pharma Limited’s generic treatment for multiple sclerosis.
Registration for the 2017 HBA New York/New Jersey area Group Mentoring Program is open now through 2/28/17.
Greenphire and Exostar announced a partnership that facilitates the adoption, accessibility and use of clinical research site payment solutions.
Lyft and Continuum Clinical announced a partnership that will help to provide transportation solutions for patients who are enrolled in pharmaceutical clinical trials.
Aetna and Humana would consider all available options for their proposed $34 billion merger, the two U.S. health insurers said one day after a court ruled against the deal due to fears it would lower competition.
